Shares in electronic components supplier e2v Technologies perked up following last Friday's announcement that its chairman had increased his stake in the company. This comes at a time when e2v has been hit by industrial strife at its Grenoble facility. It anticipates that this will reduce turnover by around £7m in the current quarter. That will significantly reduce group profitability.Chris Geoghegan acquired 123,512 shares at 40p each. He invested just short of £50,000. This takes his stake to 203,512 shares, equivalent to 0.1% of e2v. Net debt was £52.4m at the end of 2009, following the rights issue and placing at 70p a share that raised £55.8m gross just before the end of last year. The company is in the middle of a restructuring of the business in the UK as well as at Grenoble. There was a negative share price reaction to drug developer Vernalis buying back all the rights to royalties receivable from Menarini's sales of acute migraine treatment frovatriptan. Vernalis has paid Paul Capital Healthcare $32.57m (£21m) for these rights. PCH has also been granted 2.1 warrants over Vernalis shares. PCH paid €18.4m in April 2008 for a 90% interest in the royalties. Vernalis gets 25.25% of sales of frovatriptan in the EU and Central America. In 2009, sales were €32.4m. This will give Vernalis a sustainable income stream. FTSE TechMARK - RisersTrafficmaster (TFC) 33.00p +4.76%Alterian (ALN) 149.50p +4.55%Emblaze (BLZ) 45.50p +4.00%Telecity Group (TCY) 406.10p +2.94%Alphameric (ALM) 28.00p +2.75%Kewill (KWL) 105.00p +2.69%E2V Technologies (E2V) 39.50p +2.60%Puricore (PURI) 11.00p +2.33%Biocompatibles International (BII) 255.00p +2.00%Ark Therapeutics (AKT) 13.75p +1.85%FTSE TechMARK - FallersSkyepharma (SKP) 63.00p -5.97%Sepura (SEPU) 47.00p -5.05%Gresham Computing (GHT) 18.50p -3.90%Vernalis (VER) 72.00p -3.36%Morse (MOR) 37.50p -3.23%Axis-Shield (ASD) 377.00p -2.84%Phoenix IT Group (PNX) 280.00p -2.44%Oxford Biomedica (OXB) 11.00p -2.22%Torotrak (TRK) 24.00p -2.04%Renishaw (RSW) 607.00p -1.94%